title: STAR 3 randomized controlled trial to compare sensor-augmented insulin pump therapy with multiple daily injections in the treatment of type 1 diabetes: research design, methods, and baseline characteristics of enrolled subjects.
abstract: BACKGROUND
  Sensor-augmented pump therapy (SAPT) integrates real-time continuous glucose monitoring (RT-CGM) with continuous subcutaneous insulin infusion (CSII) and offers an alternative to multiple daily injections (MDI). Previous studies provide evidence that SAPT may improve clinical outcomes among people with type 1 diabetes. Sensor-Augmented Pump Therapy for A1c Reduction (STAR) 3 is a multicenter randomized controlled trial comparing the efficacy of SAPT to that of MDI in subjects with type 1 diabetes.
  
  
  METHODS
  Subjects were randomized to either continue with MDI or transition to SAPT for 1 year. Subjects in the MDI cohort were allowed to transition to SAPT for 6 months after completion of the study. SAPT subjects who completed the study were also allowed to continue for 6 months. The primary end point was the difference between treatment groups in change in hemoglobin A1c (HbA1c) percentage from baseline to 1 year of treatment. Secondary end points included percentage of subjects with HbA1c < or =7% and without severe hypoglycemia, as well as area under the curve of time spent in normal glycemic ranges. Tertiary end points include percentage of subjects with HbA1c < or =7%, key safety end points, user satisfaction, and responses on standardized assessments.
  
  
  RESULTS
  A total of 495 subjects were enrolled, and the baseline characteristics similar between the SAPT and MDI groups. Study completion is anticipated in June 2010.
  
  
  CONCLUSIONS
  Results of this randomized controlled trial should help establish whether an integrated RT-CGM and CSII system benefits patients with type 1 diabetes more than MDI.
authors.affiliation: Diabetes/Endocrinology, Department of Medicine, Vanderbilt University, 2213 Garland Avenue, Nashville, TN 37232-0475, USA. steve.davis@vanderbilt.edu
authors.forename: Stephen N
authors.initials: SN
authors.lastname: Davis
authors.forename: Edward S
authors.initials: ES
authors.lastname: Horton
authors.forename: Tadej
authors.initials: T
authors.lastname: Battelino
authors.forename: Richard R
authors.initials: RR
authors.lastname: Rubin
authors.forename: Kevin A
authors.initials: KA
authors.lastname: Schulman
authors.forename: William V
authors.initials: WV
authors.lastname: Tamborlane
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy*; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007267:Injections; D007328:Insulin / Q000008:administration & dosage*; D007332:Insulin Infusion Systems; D008875:Middle Aged; D012107:Research Design; D055815:Young Adult
chemical_list: D007004:Hypoglycemic Agents; D007328:Insulin